Letter to the Editor: “FDA’s compassionate-use program offers early access without compromising drug trials”

Washington Post, April 24, 2014   The April 22 front-page article “FDA relents in battle against a cruel disease,” about parents urging the Food and Drug Administration to approve a promising drug for Duchenne muscular dystrophy, pulled on the heartstrings. However, there … Continue reading